Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have received a consensus recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.00.

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, September 21st. HC Wainwright reissued a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Finally, Citigroup restated a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th.

Hedge Funds Weigh In On Citius Pharmaceuticals

An institutional investor recently bought a new position in Citius Pharmaceuticals stock. BlackRock Inc. bought a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned 0.25% of Citius Pharmaceuticals at the end of the most recent quarter. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $0.47 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.40 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $12.76 million, a PE ratio of -0.28 and a beta of 1.00. Citius Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $2.19. The stock has a 50-day moving average price of $0.58 and a two-hundred day moving average price of $0.63.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. Analysts expect that Citius Pharmaceuticals will post -2.03 EPS for the current year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for oncology and critical care. The company’s pipeline has included therapies intended to address unmet medical needs in hospital and cancer-care settings.

Citius’ lead oncology product is LYMPHIR (denileukin diftitox-cxdl), an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.